NEUP

Neuphoria Therapeutics (NEUP)

About Neuphoria Therapeutics (NEUP)

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Details

Daily high

$4.04

Daily low

$3.81

Price at open

$3.86

52 Week High

$21.40

52 Week Low

$2.77

Market cap

7.3M

Dividend yield

0.00%

Volume

42,004

Avg. volume

86,478

P/E ratio

-.16

Neuphoria Therapeutics News